首页> 美国卫生研究院文献>Chemical Science >Enabling synthesis in fragment-based drug discovery by reactivity mapping: photoredox-mediated cross-dehydrogenative heteroarylation of cyclic amines
【2h】

Enabling synthesis in fragment-based drug discovery by reactivity mapping: photoredox-mediated cross-dehydrogenative heteroarylation of cyclic amines

机译:通过反应性作图实现基于片段的药物发现中的合成:光氧化还原介导的环胺的交叉脱氢杂芳基化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In fragment-based drug discovery (FBDD), a weakly binding fragment hit is elaborated into a potent ligand by bespoke functionalization along specific directions (growth vectors) from the fragment core in order to complement the 3D structure of the target protein. This structure-based design approach can present significant synthetic challenges, as growth vectors often originate on sp2 or sp3 ring carbons which are not the most synthetically accessible points on the fragment. To address this issue and expedite synthesis in FBDD, we established a nanogram-to-gram workflow for the development of enabling synthetic transformations, such as the direct C–H functionalization of heterocycles. This novel approach deploys high-throughput experimentation (HTE) in 1536-well microtiter plates (MTPs) facilitated by liquid handling robots to screen reaction conditions on the nanomolar scale; subsequently the reaction is upscaled in a continuous flow to generate gram-quantities of the material. In this paper, we disclose the use of this powerful workflow for the development of a photoredox-mediated cross-dehydrogenative coupling of fragments and medicinally relevant heterocyclic precursors via Minisci-type addition of α-amino radicals to electron-deficient heteroarenes. The optimized reaction conditions were employed on the milligram-scale on a diverse set of 112 substrates to map out structure–reactivity relationships (SRRs) of the transformation. The coupling exhibits excellent tolerance to a variety of functional groups and N-rich heteroarenes relevant to FBDD and was upscaled in a continuous flow to afford gram-quantities of pharmaceutically relevant sp2–sp3 privileged architectures.
机译:在基于片段的药物发现(FBDD)中,通过沿片段核心的特定方向(增长载体)定制功能化,将弱结合的片段命中精细化为有效的配体,以补充靶蛋白的3D结构。这种基于结构的设计方法可能会带来重大的合成挑战,因为生长载体通常起源于sp 2 或sp 3 环碳,而碳不是片段上最易于合成的点。为了解决此问题并加快FBDD中的合成,我们建立了纳克级至克级的工作流程,以开发实现合成转化的方法,例如杂环的直接C–H功能化。这种新颖的方法在液体处理机器人的协助下,在1536孔微量滴定板(MTP)中部署了高通量实验(HTE),以纳摩尔规模筛选反应条件。随后,将反应以连续流动的方式放大以产生克量的材料。在本文中,我们公开了利用这种功能强大的工作流程,通过将Mini-ci类型的α-氨基自由基加到缺电子的杂芳烃上,开发片段与医学相关杂环前体的光氧化还原介导的交叉脱氢偶联。在112种不同底物上以毫克级为单位优化了反应条件,以绘制出转化的结构-反应性关系(SRR)。偶联物对各种功能基团和​​与FBDD相关的富氮杂芳基表现出优异的耐受性,并且在连续流动中进行了规模放大,从而获得了与药学相关的sp 2 –sp 3 < / sup>特权架构。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号